Expert Speaks to Disparities in Stem Cell Transplant for Blood Cancers

Commentary
Video

Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.

A significant portion of Black patients with hematologic malignancies who are eligible for hematopoietic stem cell transplant do not undergo the procedure, posing a significant challenge, according to Usama Gergis, MD, MBA.

In an interview with CancerNetwork®, Gergis, the director of Stem Cell Transplant and Cellular Therapy Program at Jefferson Health, detailed not only disparities in stem cell transplant by race and ethnicity, but the significant number of patients who are not receiving treatment overall.

According to data from the Be the Match Registry, 79% of White patients are able to find a match in the stem cell donor registry compared with 29% of Black patients, 47% of Asian/Pacific Islander patients, and 48% of Hispanic/Latino patients.

Transcript:

We can take this as an example of a complex procedure that requires a lot of resources. For allogeneic bone marrow transplant, there is someone who has blood cancer requiring hematopoietic stem cells from a donor. In the United States for all eligible patients, more than half do not get to have this complex procedure—more than half [at] 55%.

In looking at the ethnicity distribution here, there is a stark difference between Caucasians and African Americans. For African Americans, approximately 10% or 11% of patients who are eligible for allogeneic transplant actually get the procedure. The same goes for Hispanic and Asian [patients, as well as] Caucasians patients to a lesser extent. If you take allogeneic, bone marrow transplant, [also known as] stem cell transplant, as an example of a complex procedure, I think that this [challenge is prevalent.]

Reference

How does a patient's ethnic background affect matching? Be the Match. Accessed October 13, 2023. https://bit.ly/3PNjTt6

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content